- Home
- Automated
- List of product information
- STAQUIS OINTMENT 2% W/W [SIN16613P]
STAQUIS OINTMENT 2% W/W [SIN16613P]
Active ingredients: STAQUIS OINTMENT 2% W/W
Last updated 26 October 2025
On this page
Product Info
STAQUIS OINTMENT 2% W/W
[SIN16613P]
Product information
Active Ingredient and Strength | CRISABOROLE - 2% W/W |
Dosage Form | OINTMENT |
Manufacturer and Country | PHARMACIA & UPJOHN COMPANY LLC (SUBSIDIARY OF PFIZER INC) - UNITED STATES |
Registration Number | SIN16613P |
Licence Holder | PFIZER PRIVATE LIMITED |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | D11AH06 |
4.1. Therapeutic indications
STAQUIS is indicated for topical treatment of mild to moderate atopic dermatitis in patients 3 months of age and older (see section 5.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
4.2. Posology and method of administration
Posology
Adults
STAQUIS is to be applied as a thin layer twice daily to affected areas for the management of active disease. Once clinical effect is achieved, consider reducing application to once daily for maintenance treatment. The efficacy of STAQUIS for continuous twice daily application beyond 8 weeks has not been studied in a clinical trial (see section 5.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
STAQUIS can be used on all skin areas, including the face, neck, and intertriginous areas. The use of STAQUIS on the scalp has not been studied.
Pediatric population
For children and adolescents (3 months to 17 years of age) the posology is the same as for adults. The safety and effectiveness of STAQUIS in pediatric patients below the age of 3 months have not been established.
Special populations
Clinical trials with hepatic or renal impaired subjects have not been conducted. However, dosage adjustment is not expected to be necessary in subjects with mild to moderate hepatic impairment or in subjects with renal impairment.
Clinical studies of STAQUIS did not include sufficient numbers of subjects 65 years of age and over to determine whether they respond differently from younger subjects. However, dosage adjustment is not expected to be necessary in this patient population.
Method of administration
STAQUIS is for topical use only and not for oral, ophthalmic, or intravaginal use.
STAQUIS has not been studied under occlusion. However, clinical experience available for use of the ointment under occlusion (i.e., diapers/nappies or clothing) has not shown the necessity for any dosage adjustment.
Patients should be instructed to wash their hands after applying STAQUIS, unless it is their hands that are being treated. If someone else applies STAQUIS to the patient, they too should wash their hands after application.
4.3. Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.